key: cord-0715417-a6ny5xx1 authors: Kaul, Pallvi; Pal Singh, Mahendra; Pasricha, Rajesh; Kumar Garg, Pankaj title: Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: another option in the therapeutic armamentarium date: 2020-06-04 journal: Oral Oncol DOI: 10.1016/j.oraloncology.2020.104839 sha: 8a6fea05b9207b5a8a5afc069570e2eed4178bcf doc_id: 715417 cord_uid: a6ny5xx1 nan Dear Editor, Oral cancer is the one of the common head and neck malignancy amongst males globally. Surgery remains the mainstay of treatment both in early and advanced stage disease and is associated with a significant improvement in overall survival [1] . COVID-19 pandemic has literally halted the elective cancer surgeries worldwide. Almost all the guidelines have suggested delaying the elective surgery whenever possible [2] . Many studies have suggested poor perioperative outcomes in Sars-Cov-2 positive patients who undergo surgery. This has posed a therapeutic and ethical dilemma to the surgeons as delaying the surgery for advanced oral cancer will prove to be a double whammy -inferior overall survival and poor quality of life. The role of neoadjuvant chemotherapy in advanced oral cancer is not yet fully established. A triple agent induction chemotherapy including Taxanes, platinum and 5-FU is the usual first line therapy but has a significant toxicity profile [3] [4] [5] . As true for surgery, it is recommended to avoid intravenous toxic chemotherapy during Covid-19 pandemic as well. This further leaves the oncologists dealing with the patients with advanced oral cancer in a tight spot. In the era of personalized medicine, where the repertoire of drugs directed against tumor cells has greatly increased, selecting an efficacious and apt drug regimen for an interim period till the time a definitive treatment can be administered to the patients remains a challenge not yet explicitly addressed. Recent evidence -one publication the journal Oral Oncology [6] and another conference presentation during ASCO 2020 virtual meeting [7] -supporting the role of Methotrexate based oral chemotherapy for the advanced oral cancer has turned out to be a silver lining amidst critical time of COVID-19 pandemic. In their experience of 23 patients with locally advanced T4a tumors treated with weekly oral Methotrexate and daily Celecoxib, Sultania et al [6] reported that disease progressed in only 3 (13%). Moreover, none of the patient had grade III or IV toxicity. A phase III trial, presented at ASCO 2020, [7] 30.2% grade 3 or above adverse events, p= .01). Though the trial addresses the patient population treated with a palliative intent, yet the benefit can be extrapolated in patients with non-metastatic advanced oral cancer who cannot be currently operated upon due to COVID19 pandemic and cannot be prescribed potentially toxic triple agent intravenous chemotherapy also. "A bird in the hand is worth two in the bush" -adhering to this philosophy and considering the ease of prescription, home-based nature of therapy, proven effectiveness, and a likely improvement in survival, Oral Methotrexate and Celecoxib therapy may be the best bet in the management of patients with advanced oral cancer during the current crisis. Future Bayesian approach trials can only provide an affirmative answer to a best treatment regimen for the current scenario. The authors declared that there is no conflict of interest. Operable Oral Tongue Squamous Cell Cancer: 15 Years Experience at a Tertiary Care Center in North India Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic Oral Cancer Surgery and COVID pandemic -Metronomic Therapy shows a promising role while awaiting surgery Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study The authors confirm that they have no conflicts of interests to declare.